secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003931
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics appoints new CMO and CDO; prior CMO departed
--------------------------------------------------------------

- Dr. Celia Lin separated as CMO effective Jan 3, 2024; received target 2023 bonus and severance.
- Dr. Robert Brenner appointed CMO effective Jan 3, 2024; brings 25+ yrs nephrology and biotech experience.
- William D. Turner appointed CDO effective immediately; led drug development, NDA/MAA filings at Sierra and Aimmune.
- Both execs to support atacicept Phase 3 trial in IgA nephropathy and pipeline development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312524003931/0001193125-24-003931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312524003931/d110151d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer